Bronchiolitis Case Study Outline

Scope and Purpose of the Guideline The objective of the reviewed guideline is to deliver evidence-based information regarding the diagnosis, management, treatment, and prevention of bronchiolitis in children. The target population for intended use of this guideline is children, aged 1 month through 23 months old. However, children with certain preexisting conditions were excluded from this population. Children with comorbid respiratory ailments are included in the discussion of prevention of bronchiolitis, but are not included in this guideline’s discussion of management. Children who are immunocompromised, for example those with (HIV) human immunodeficiency virus or those who have undergone organ or stem cell transplant, are not included within the scope of
Within diagnosis, the authors included the assessment of risk factors and presentation upon physical examination. Treatments for management of bronchiolitis that were considered included nebulized hypertonic saline, fluid replacement, the option of initiating supplemental oxygen and/or continuous pulse oximetry monitoring, and antibacterial medications. The authors reviewed the use of palivizumab, the effect of hand hygiene, possible exposure to tobacco smoke, breast feeding, and family education within the category of prevention in this clinical practice guideline. The outcomes considered by the authors included efficacy of diagnostic tools, symptom improvement, mortality and morbidity, hospitalization rate, length of stay for hospitalizations, incidence of respiratory syncytial virus (RSV) infection, and cost-effectiveness. The population of interest was clearly defined, and the area in which this guideline applies The interventions and outcomes considered in this guideline were defined using a strength rating scheme and expert